Compounds > adenosine diphosphate ribose

adenosine diphosphate ribose and Urinary Bladder Neoplasms

adenosine diphosphate ribose has been researched along with Urinary Bladder Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Lee, HW; Seo, HK1
Barber, J; Birtle, AJ; Brock, S; Crabb, SJ; Dempsey, L; Enting, D; Faust, G; Frew, J; Gale, J; Hinsley, S; Hussain, S; Jones, RJ; Lees, K; McGovern, U; Parikh, O; Powles, T; Ratnayake, G; Song, Y; Soulis, E; Sundar, S; Trevethan, A1

Trials

1 trial(s) available for adenosine diphosphate ribose and Urinary Bladder Neoplasms

ArticleYear
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-01, Volume: 41, Issue:1

    Topics: Adenosine Diphosphate Ribose; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Transitional Cell; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerases; Urinary Bladder Neoplasms

2023

Other Studies

1 other study(ies) available for adenosine diphosphate ribose and Urinary Bladder Neoplasms

ArticleYear
Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder.
    Investigative and clinical urology, 2022, Volume: 63, Issue:4

    Topics: Adenosine Diphosphate Ribose; Carcinoma, Transitional Cell; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Urinary Bladder; Urinary Bladder Neoplasms

2022